Arcellx Inc. announced that it will present new research on its D-Domain platform technology and commercial preparedness for anito-cel, a potential treatment for multiple myeloma, at the 2026 Tandem Meetings scheduled for February 4-7, 2026, in Salt Lake City, Utah. The company will share three presentations, including data supporting anito-cel's unique pharmacology profile, a simulation model analyzing treatment sequencing with CAR T-cell therapies and bispecific antibodies in relapsed/refractory multiple myeloma, and a study examining geographic inequities in CAR T access for multiple myeloma patients in the United States. The results of these studies will be presented at the upcoming conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcellx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260121747816) on January 21, 2026, and is solely responsible for the information contained therein.